

Sun Pharma's Para IV Pipeline Analysis

<https://marketpublishers.com/r/S609CE19395EN.html>

Date: June 2011

Pages: 27

Price: US\$ 350.00 (Single User License)

ID: S609CE19395EN

Abstracts

Sun Pharma has the pipeline of ~29 Para IVs having branded sales of ~\$25b. Among its Para IV pipeline the confirmed opportunities (branded sales of ~ \$7.8b) are Gleevec, Namenda, Comtan, Stalevo, Temodar, Eloxatin, Clarinex, Vanos, and Lexapro. Among these Gleevec, Stalevo and Eloxatin could be the most lucrative ones. Other than these Para IVs, we believe Nexium IV and Ryzolt have the potential to fetch considerable upside. We expect PAT of ~\$557m from Para IVs which is ~ 5% of Sun's market cap

Sun Pharma has been largely successful in Para IV litigations, with successes like Gemzar, Eloxatin and Prandin. Based on this, we believe Sun Pharma has the potential to throw surprises from its pipeline.

Contents

COMPANIES MENTIONED

SUN PHARMA, SUNP

I would like to order

Product name: Sun Pharma's Para IV Pipeline Analysis

Product link: <https://marketpublishers.com/r/S609CE19395EN.html>

Price: US\$ 350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S609CE19395EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970